Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.63 |
| ▸ | CA1 | P00915 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358755 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 | |
| SCHEMBL333450 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 | |
| SCHEMBL9187083 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 | |
| SCHEMBL333850 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 | |
| SCHEMBL333256 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 | |
| SCHEMBL2131976 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 | |
| SCHEMBL2120555 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 | |
| SCHEMBL15239 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 | |
| SCHEMBL2121081 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 | |
| SCHEMBL27603020 | 1.00 | CA2 (0.63) | CA2CA1MAPK1NAAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119015394-A | Sulfur-containing compound preparation, and preparation method and application thereof | 上海优斐斯生物科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118431472-A | Binder composition, slurry composition, electrode, and secondary battery | 上海百公里新材料科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-115209866-A | Mixed cosmetic comprising creamy compacted powder | 艺术化妆品有限公司 | 2022-10-18 | — | — | CN | claimed |
| EP-1782791-B2 | Cosmetic composition comprising a cationic surfactant,a liquid fatty material and a sorbitan ester | OREAL (FR) | 2019-01-23 | — | — | EP | claimed |
| US-10071040-B2 | Cosmetic composition comprising a cation, a liquid fatty substance and a sorbitan ester, and cosmetic treatment process | L'OREAL (FR) | 2018-09-11 | — | — | US | claimed |
| EP-2932957-B1 | CLEANSING COSMETICS | NOF CORP (JP) | 2017-07-19 | — | — | EP | claimed |
| EP-2968248-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | Nal Pharmaceuticals Ltd. (CN) | 2016-01-20 | — | — | EP | claimed |
| EP-2932957-A1 | CLEANSING COSMETICS | NOF Corporation (JP) | 2015-10-21 | — | — | EP | claimed |
| WO-2014152454-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | NAL PHARMACEUTICALS, LTD. (CN) | 2014-09-25 | — | — | WO | claimed |
| US-20140271866-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | NAL PHARMACEUTICALS, LTD. (HK) | 2014-09-18 | — | — | US | claimed |
| EP-1782791-B1 | Cosmetic composition comprising a cationic surfactant,a liquid fatty material and a sorbitan ester | OREAL (FR) | 2010-07-07 | — | — | EP | claimed |
| US-7417162-B2 | Oily ingredient for cosmetic preparation and cosmetic preparation | KYOWA YUKA CO., LTD. (JP) | 2008-08-26 | — | — | US | claimed |
| US-20070122508-A1 | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | HELIXIR CO., LTD. (KR) | 2007-05-31 | — | — | US | claimed |
| US-20070104671-A1 | Cosmetic composition comprising a cation, a liquid fatty substance and a sorbitan ester, and cosmetic treatment process | L'OREAL S.A. (FR) | 2007-05-10 | — | — | US | claimed |
| US-6797374-B2 | MULTILAYER; NONMAGNETIC SUPPORT, MAGNETIC LAYER CONTAINING FATTY ESTER LUBRICANT; DURABILITY, WEAR RESISTANCE | TDK CORPORATION (JP) | 2004-09-28 | — | — | US | claimed |
| US-5905102-A | COAGULATION OF PIGMENTS, DECREASING WRITING DENSITY DUE TO SEDIMENTATION, CLOGGING THE PEN POINTS AND OXIDATION OF CARBON BLACK | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 1999-05-18 | — | — | US | claimed |
| US-12630654-B2 | Emulsion particle-containing aqueous dispersion | NIPPON SHOKUBAI CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| CN-122005622-A | Composition for improving, preventing or treating vaginitis or vulvitis comprising lactobacillus salivarius HHuMin-U | 比菲德股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-1993010101-A1 | BENZIMIDAZOLE ANTHELMINTIC AGENTS | PFIZER LIMITED (GB) | 1993-05-27 | — | — | WO | disclosed |
| US-4822417-A | ERASABLE, NONDRYING | PENTEL KABUSHIKI KAISHA (JP) | 1989-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070104671-A1 | Cosmetic composition comprising a cation, a liquid fatty substance and a sorbitan ester, and cosmetic treatment process | KRT18, CUTA, CD44 | CA2 1283/4885CA1 1570/4885MAPK1 1793/4885 |
| US-12630654-B2 | Emulsion particle-containing aqueous dispersion | CLTB, CLTA, APOB | CA2 3161/4885CA1 3028/4885MAPK1 3524/4885 |
| US-10071040-B2 | Cosmetic composition comprising a cation, a liquid fatty substance and a sorbitan ester, and cosmetic treatment process | KRT18, CUTA, CD44 | CA2 1283/4885CA1 1570/4885MAPK1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.